|1.||Vaddi, Kris: 3 articles (04/2010 - 11/2009)|
|2.||Fridman, Jordan S: 3 articles (04/2010 - 11/2009)|
|3.||Combs, Andrew P: 3 articles (04/2010 - 11/2009)|
|4.||Burn, Timothy C: 2 articles (04/2010 - 11/2009)|
|5.||Caulder, Eian: 2 articles (01/2010 - 11/2009)|
|6.||Sparks, Richard B: 2 articles (01/2010 - 11/2009)|
|7.||Li, Jun: 2 articles (01/2010 - 11/2009)|
|8.||Patel, Jay: 1 article (04/2010)|
|9.||Haley, Patrick J: 1 article (04/2010)|
|10.||Hedvat, Cyrus: 1 article (04/2010)|
|1.||Primary Myelofibrosis (Myelosclerosis)
04/08/2010 - "Compared with vehicle treatment, INCB16562 treatment improved survival, normalized white blood cell counts and platelet counts, and markedly reduced extramedullary hematopoeisis and bone marrow fibrosis. "
04/08/2010 - "Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis."
|2.||Hematologic Neoplasms (Hematological Malignancy)
11/15/2009 - "In vivo, INCB16562 reduced malignant cell burden, reversed splenomegaly and normalized splenic architecture, improved body weight gains, and extended survival in a model of JAK2V617F-driven hematologic malignancy. "
11/15/2009 - "These data showed that administration of the dual JAK1/2 inhibitor INCB16562 reduces malignant cell burden, normalizes spleen size and architecture, suppresses inflammatory cytokines, improves weight gain, and extends survival in a rodent model of JAK2V617F-driven hematologic malignancy. "
01/01/2010 - "INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support."
01/01/2010 - "Moreover, the proliferation and survival of myeloma cells dependent on IL-6 for growth, as well as the IL-6-induced growth of primary bone marrow-derived plasma cells from a multiple myeloma patient, were inhibited by INCB16562. "
|2.||Interleukin-6 (Interleukin 6)